Case Report
PD-1 Checkpoint Blockade in Patients for Acute Myeloid Leukemia after HSCT Relapse Resulted in Severe GVHD and sHLH
Table 1
Frequency of acute treatment, emergent GVHD, and laboratory findings: pretreatment, day 14 after the administration of carrizumab.
| | | Case 1 | Case 2 | | Pretreatment | Day 14 | Pretreatment | Day 14 |
| | Stage of aGVHD | | Skin | Stage 0 | Stage 4 | Stage 1 | Stage 4 | | GI | Stage 0 | Stage 4 | Stage 0 | Stage 4 | | Liver | Stage 0 | Stage 2 | Stage 0 | Stage 2 |
| | HLH | | Hemoglobin (g/L) | 146 | 85 | 85 | 77 | | Platelet (×109/L) | 194 | 61 | 108 | 16 | | Neutrophil count (×109/L) | 1.64 | 1.58 | 1.64 | 0.03 | | Bilirubin (mg/dL) | 0.88 | 4 | 0.22 | 4.11 | | Ferritin (ng/mL) | 6253.6 | 20920 | 3796.7 | 10450 | | Fibrin (g/L) | 2.81 | 0.71 | 2.85 | 4.94 | | Triglyceride (mmol/L) | 1.76 | 4.94 | 2.56 | 5.35 | | sIL-2R (U/mL) | — | 12365 | — | 76806 | | NK cell activity (<15.11%) | — | 11.22 | — | 8.61 |
|
|
Acute GVHD stage/grade and responses were scored according to consensus and National Institutes of Health (NIH) criteria, GI = gastrointestinal.
|
